This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: University System of Maryland, Other. Active years: 2002-2022.
Company Filing History:
3 out of 2,022 
1 out of 834,350 Years Active: 2002-2022
Title: Alonso Heredia: Innovator in HIV and Cancer Treatment
Introduction
Alonso Heredia is a notable inventor based in Washington, DC, who has made significant contributions to the fields of HIV and cancer treatment. With a total of 4 patents, his work focuses on innovative methods to combat these serious health issues.
Latest Patents
Heredia's latest patents include groundbreaking methods for treating HIV and cancer in patients infected with HIV. One of his notable inventions involves the use of mTOR inhibitors to provide therapeutically effective treatment. Specifically, he has developed methods for administering mTOR inhibitors such as INK128, GSK2126458, AZD2014, or Torin-2 to patients in need. Additionally, he has created compositions aimed at down-regulating CCR5 expression, which is crucial for reducing the entry points of HIV into T cells. This invention involves manipulating the cell cycle in activated lymphocytes to enhance the effectiveness of antiviral agents.
Career Highlights
Throughout his career, Alonso Heredia has worked with the University System of Maryland, where he has contributed to various research initiatives. His innovative approaches have garnered attention in the scientific community, particularly for their potential impact on public health.
Collaborations
Heredia has collaborated with esteemed colleagues such as Robert R. Redfield and Charles E. Davis, Jr. These partnerships have further enriched his research and development efforts in the field of HIV and cancer treatment.
Conclusion
Alonso Heredia stands out as a dedicated inventor whose work in HIV and cancer treatment showcases his commitment to improving health outcomes. His innovative patents reflect a deep understanding of complex medical challenges and a drive to find effective solutions.